Total Number of Communication Reports: 6
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Economic Development, Health, Industry, Science and Technology
|
Investment from governments are being requested to further Entos Pharmaceuticals' research and development of genetic medicines, as well as to assist in funding an innovation centre and manufacturing facility for genetic medicines.
|
Grant, Contribution or Other Financial Benefit
|
Entos Pharmaceuticals is developing a COVID-19 vaccine. Entos wishes to communicate and seek the federal government's support for a “made in Canada” solution to COVID-19.
John Lewis, Chief Executive Officer
End date of the last completed financial year: 2024-05-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Government of Alberta | $15,500,000.00 | No |
National Research Council (NRC) | $10,000,000.00 | Yes |
Address:
Unit 4550, 10230 Jasper Avenue
Edmonton, AB T5J 4P6
Canada
Telephone number:
780-862-7445
Entos Pharmaceuticals is not a subsidiary of any other parent companies.
Entos Pharmaceuticals does not have any subsidiaries that could have a direct interest in the outcome of the undertaking